| human | Q5 |
| P496 | ORCID iD | 0000-0002-2947-1063 |
| P3829 | Publons author ID | 2269422 |
| P1053 | ResearcherID | G-8375-2016 |
| P1153 | Scopus author ID | 14017700600 |
| P108 | employer | Regina Elena National Cancer Institute | Q69734359 |
| P734 | family name | Bossi | Q21492312 |
| Bossi | Q21492312 | ||
| Bossi | Q21492312 | ||
| P735 | given name | Gianluca | Q1522479 |
| Gianluca | Q1522479 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q39042161 | Abscopal effect of radiation therapy: Interplay between radiation dose and p53 status |
| Q92283453 | Approaching the challenges of MKK3/p38delta MAPK targeting for therapeutic purpose in colorectal cancer |
| Q39667788 | Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation. |
| Q35590396 | Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy |
| Q60393612 | Corrigendum |
| Q61814437 | Cytokine Modulation in Breast Cancer Patients Undergoing Radiotherapy: A Revision of the Most Recent Studies |
| Q33709136 | Degradation of mutant p53H175 protein by Zn(II) through autophagy. |
| Q51757944 | Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. |
| Q42288961 | HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice. |
| Q35168034 | In vivo and in vitro evidence that PPARγ ligands are antagonists of leptin signaling in breast cancer |
| Q54473491 | Inhibition of Leydig tumor growth by farnesoid X receptor activation: the in vitro and in vivo basis for a novel therapeutic strategy. |
| Q36525180 | Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. |
| Q54110522 | Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer. |
| Q34010406 | Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells |
| Q39877577 | MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. |
| Q91151365 | MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer |
| Q35891239 | Molecular imaging of nuclear factor-Y transcriptional activity maps proliferation sites in live animals. |
| Q38977664 | Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. |
| Q55026448 | Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. |
| Q33825046 | Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function |
| Q34163572 | PKC theta ablation improves healing in a mouse model of muscular dystrophy |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q39919668 | Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. |
| Q41007292 | Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells. |
| Q112702414 | SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma |
| Q83855474 | Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis |
| Q39961155 | Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models |
| Q36347205 | Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications. |
| Q35986990 | The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells |
| Q92121511 | The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments |
| Q45871670 | Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy |
Search more.